AC
SMMT icon

AXQ Capital’s Summit Therapeutics SMMT Stock Holding History

AXQ Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
93,624
+46,356
+98% +$822K 0.15% 219
2026
Q1 		$896K Sell
47,268
-34,251
-42% -$554K 0.12% 265
2025
Q4 		$1.43M Buy
81,519
+64,051
+367% +$1.2M 0.32% 83
2025
Q3 		$361K Buy
+17,468
New +$424K 0.14% 268

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

AXQ Capital's SMMT Position: Q2 2026 in Review

AXQ Capital increased its Summit Therapeutics (SMMT) stake by 98% in Q2 2026, buying an estimated $822K and bringing the position to 93,624 shares worth $1.36M. The position accounts for 0.15% of the portfolio, ranked #219.

AXQ Capital first reported a position in SMMT in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.43M in Q4 2025. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • AXQ Capital held 93,624 shares of Summit Therapeutics worth $1.36M as of Q2 2026.
  • AXQ Capital bought 46,356 Summit Therapeutics shares in Q2 2026, an estimated $822K.
  • Summit Therapeutics made up 0.15% of AXQ Capital's portfolio in Q2 2026, its #219 holding.
  • AXQ Capital first reported a position in Summit Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • AXQ Capital's Summit Therapeutics position peaked at $1.43M in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.